After a complete response letter and a subsequent biologics license application resubmission, denileukin diftitox has been approved by the FDA.
Approval Alert | Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma
Advertisement
Advertisement
Trending on CancerNetwork
1
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
2
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
3
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
4
PDS0101/Pembrolizumab Yields 39.3-Month Median OS in HPV16-Positive HNSCC
5